newsfilter
← Latest News
GlobeNewswire·

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced positive feedback from the FDA on the Company's proposed single confirmatory Phase 3 study of